» Articles » PMID: 23737042

The Protective Effect of Crocin on the Amyloid Fibril Formation of Aβ42 Peptide in Vitro

Overview
Publisher Biomed Central
Date 2013 Jun 6
PMID 23737042
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Aβ is the main constituent of the amyloid plaque found in the brains of patients with Alzheimer's disease. There are two common isoforms of Aβ: the more common form, Aβ40, and the less common but more amyloidogenic form, Aβ42. Crocin is a carotenoid from the stigma of the saffron flower and it has many medicinal properties, including antioxidant effects. In this study, we examined the potential of crocin as a drug candidate against Aβ42 amyloid formation. The thioflavin T-binding assay and electron microscopy were used to examine the effects of crocin on the extension and disruption of Aβ42 amyloids. To further investigate the relationship between crocin and Aβ42 structure, we analyzed peptide conformation using the ANS-binding assay and circular dichroism (CD) spectroscopy. An increase in the thioflavin T fluorescence intensity upon incubation revealed amyloid formation in Aβ42. It was found that crocin has the ability to prevent amyloid formation by decreasing the fluorescence intensity. Electron microscopy data also indicated that crocin decreased the amyloid fibril content of Aβ. The ANS-binding assay showed that crocin decreased the hydrophobic area in incubated Aβ42. CD spectroscopy results also showed that the peptide undergoes a structural change to α-helical and β-turn. Our study shows that the anti-amyloidogenic effect of crocin may be exerted not only by the inhibition of Aβ amyloid formation but also by the disruption of amyloid aggregates. Therefore, crocin could be essential in the search for therapies inhibiting aggregation or disrupting aggregation.

Citing Articles

Saffron, a Potential Bridge between Nutrition and Disease Therapeutics: Global Health Challenges and Therapeutic Opportunities.

Mir R, Tyagi A, Hussain S, Almalki M, Zeyad M, Deshmukh R Plants (Basel). 2024; 13(11).

PMID: 38891276 PMC: 11174376. DOI: 10.3390/plants13111467.


Therapeutic effects of saffron and its components on neurodegenerative diseases.

Hamedani S, Pourmasoumi M, Zarifi S, Askari G, Jamialahmadi T, Bagherniya M Heliyon. 2024; 10(2):e24334.

PMID: 38298664 PMC: 10827773. DOI: 10.1016/j.heliyon.2024.e24334.


Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation.

Monteiro K, Aquino T, Silva-Junior E CNS Neurol Disord Drug Targets. 2023; 23(10):1234-1250.

PMID: 38018200 DOI: 10.2174/0118715273273539231114095300.


The Effect of Ultrasonication on the Fibrillar/ Oligomeric Structures of Aβ at Different Concentrations.

Faridi N, Sanjari-Pour M, Wang P, Bathaie S Protein J. 2023; 42(5):575-585.

PMID: 37634212 PMC: 10480282. DOI: 10.1007/s10930-023-10138-0.


Protective Effect of Low Dose of Methamphetamine on The Amount of Extracellular Glutamine in Primary Fetal Human Astrocytes Induced by Amyloid Beta.

Soltanian B, Shasaltaneh M, Riazi G, Masoudian N Cell J. 2022; 24(3):105-111.

PMID: 35451579 PMC: 9035228. DOI: 10.22074/cellj.2022.7917.


References
1.
Burns A, Byrne E, Maurer K . Alzheimer's disease. Lancet. 2002; 360(9327):163-5. DOI: 10.1016/S0140-6736(02)09420-5. View

2.
Thomas P, Fenech M . A review of genome mutation and Alzheimer's disease. Mutagenesis. 2006; 22(1):15-33. DOI: 10.1093/mutage/gel055. View

3.
Waldemar G, Dubois B, Emre M, Georges J, McKeith I, Rossor M . Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007; 14(1):e1-26. DOI: 10.1111/j.1468-1331.2006.01605.x. View

4.
Naiki H, Gejyo F . Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999; 309:305-18. DOI: 10.1016/s0076-6879(99)09022-9. View

5.
Khurana R, Coleman C, Ionescu-Zanetti C, Carter S, Krishna V, Grover R . Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol. 2005; 151(3):229-38. DOI: 10.1016/j.jsb.2005.06.006. View